For example, resistance to anti-EGFR monoclonal antibodies in colorectal cancer and to EGFR TKIs in EGFR-mutant non-small cell lung cancer (NSCLC) can be mediated by activation of alternate RTK pathways including MET and HER2 [94]. Here, MET is linked to non-small cell lung carcinoma.